Fierceiotech

Axovant Sciences Ltd (NYSE: AXON) nearly doubled during its first few hours of trading Thursday, stirring comments about a biotech bubble. The company acquired its single product, a prospective treatment for Alzheimer's disease, for $5 million from GlaxoSmithKline plc (ADR) (NYSE: GSK) in December...